机构：[a]Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Beijing, China神经内科首都医科大学宣武医院[b]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China[c]Beijing Key Laboratory of Geriatric Cognitive Disorders, China[d]Key Neurodegenerative Laboratory of Ministry of Education of the People’s Republic of China, Beijing, China
Gelsolin (GSN) levels and matrix metalloproteinase 3 (MMP3) activity have been found to be altered in the plasma in patients with Alzheimer disease (AD). The aim of this study was to determine whether a combination of these proteins with clinical data is specific and sensitive enough for AD diagnosis. In 113 non-demented controls and 113 patients with probable AD, the plasma GSN levels were determined using the enzyme-linked immunosorbent assay (ELISA), and the plasma MMP3 activity was determined using casein zymography. Logistic regression and receiver operating characteristic (ROC) curve analysis were used to determine the diagnostic accuracy of these proteins combined with clinical data. Compared with the controls, the AD patients had significantly lower GSN levels and significantly higher MMP3 activity. Moreover, both the GSN level and MMP3 activity were significantly correlated with the MMSE scores. In AD patients, the GSN level was negatively correlated with MMP3 activity. ROC curve analysis showed that the specificity and sensitivity were 77% and 75.2%, respectively, for the combination of the following candidate biomarkers: GSN level/the total amount of A beta(42) and A beta(40), plasma MMP3 activity and clinical data. With its relatively high sensitivity and specificity, this combined biomarker panel may have potential for the screening of AD patients. 2015 (C) Elsevier Ireland Ltd. All rights reserved.
基金：
China-Canada Joint Initiative on Alzheimer’s Disease and Related Disorders (81261120571),
Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals (ZY201301),
Seed Grant of International Alliance of Translational Neuroscience(PXM2014 014226 000006),
the National Science and Technology Major Projects for “Major New Drug Innovation and Development”of the Twelfth 5-year Plan Period (2011ZX09307-001-03),
the National Key Technology R&D Program in the Eleventh Five-year Plan Period (2006BAI02B01)
the key project of the National Natural Science Foundation of China (30830045), Scientific promoting project of Beijing Institute for Brain Disorders (BIBDPXM2014 014226 000016).
第一作者机构：[a]Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Beijing, China[b]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China[c]Beijing Key Laboratory of Geriatric Cognitive Disorders, China[d]Key Neurodegenerative Laboratory of Ministry of Education of the People’s Republic of China, Beijing, China
通讯作者：
通讯机构：[*1]Department of Neurology, Xuan Wu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China.
推荐引用方式(GB/T 7714)：
Mao Peng,Jianping Jia,Wei Qin.Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease[J].NEUROSCIENCE LETTERS.2015,595:116-121.doi:10.1016/j.neulet.2015.04.014.
APA：
Mao Peng,Jianping Jia&Wei Qin.(2015).Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease.NEUROSCIENCE LETTERS,595,
MLA：
Mao Peng,et al."Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease".NEUROSCIENCE LETTERS 595.(2015):116-121
